

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

604-756

10/555,757

APPLICANT

HARBIGE et al

FILING DATE

GROUP

November 7, 2005

Unassigned



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2,077,371	04/1937	Relneck et al			
	2,617,791	11/1952	Snelling, et al			
	3,082,228	03/1963	Sutherland et al			
	3,158,541	11/1964	Sutherland et al			
	3,558,656	01/1971	Pfieffer et al			
	3,658,555	04/1972	Menz et al			
	3,671,557	06/1972	Pfieffer et al			
	3,671,563	06/1972	Pfieffer et al			
	3,676,472	07/1972	Zilliken et al			
	3,748,348	07/1973	Sreenivasan, et al			
	3,855,254	12/1974	Haighton et al			
	3,862,972	01/1975	Heslinga et al			
	3,972,907	08/1976	Baran et al			
	4,048,202	09/1977	Beek et al			
	4,181,670	01/1980	Liang et al			
	4,607,052	08/1986	Mendy et al			
	4,701,468	10/1987	Mendy et al			
	4,701,469	10/1987	Mendy et al			
	4,832,975	05/1989	Yang			
	4,851,343	07/1989	Herbert et al			
	4,867,965	09/1989	Ciaudelli			
	4,876,107	10/1989	King et al			
	4,938,984	07/1990	Traitler et al			
	5,008,126	04/1991	Klenmann et al			
	5,077,312	12/1991	Shoyab et al			
	5,151,291	09/1972	Tokairin et al			
	5,227,403	07/1993	Seto et al			
	5,306,730	04/1994	Nagai et al			
	5,583,159	12/1996	Horrobin et al			
	5,618,955	04/1997	Mechoulam et al			
	5,658,767	08/1997	Kyle et al			
	5,661,180	08/1997	DeMichele et al			
	5,663,202	09/1997	Horrobin et al			
	5,668,174	09/1997	Kawagishi et al			
	5,674,901	10/1997	Cook et al			
	5,753,702	05/1998	Bednar et al			
	5,776,913	07/1998	Olgilvie et al			
	5,834,512	11/1998	Akimoto et al			
	5,837,731	11/1998	Vaddadi			
	5,869,537	03/1999	Schreiner et al			

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial a this form with next communication to application.

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	604-756	10/555,757
(Use several sheets if necessary)	APPLICANT	
	HARBIGE et al	
	FILING DATE	TC/A.U.
	November 7, 2005	Unassigned

		5,914,347	06/1999	Grinda			
		5,922,345	07/1999	Horrobin et al			
		5,962,712	10/1999	DeMichele et al			
		5,968,809	10/1999	Knutzon et al			
		5,981,588	11/1999	Akimoto et al			
		5,990,163	11/1999	Evans et al			
		6,015,798	01/2000	Ogilvie et al			
		6,020,376	02/2000	Pariza et al			
		6,051,754	04/2000	Knutzon et al			
		6,080,787	06/2000	Carlson et al			
		6,184,251	02/2001	Stordy et al			
		6,201,022	03/2001	Mease et al			
		6,214,372	04/2001	Jerome et al			
		6,262,119	07/2001	Ferrante et al			
		6,306,908	10/2001	Carlson et al			
		6,331,568	12/2001	Horrobin et al			
		6,340,485	01/2002	Coupland et al			
		6,340,705	01/2002	Obukowicz et al			
		6,361,806	03/2002	Allen et al			
		6,410,078	06/2002	Cain et al			
		6,410,288	06/2002	Knutzon et al			
		6,426,100	07/2002	Watkins et al			
		6,426,367	07/2002	Das			
		6,479,070	11/2002	Cain et al			
		6,479,544	11/2002	Horrobin			
		6,495,536	12/2002	Masui et al			
		6,528,040	03/2003	Pearson et al			
		6,537,750	03/2004	Shorrosh			
		6,555,579	04/2003	Kritchevsky			
		6,566,543	05/2003	Mechoulam et al			
		6,576,252	06/2003	Schwartz et al			
		6,624,195	09/2003	Horrobin			
		6,630,157	10/2003	Horrobin et al			
		6,673,840	01/2004	Oh et al			
		6,677,470	01/2004	Saebo et al			
		6,864,242	03/2005	Ernest			
		6,689,812	02/2004	Peet et al			
		6,528,040	03/2003	Pearson et al			
		6,841,573	01/2005	Llewellyn			
		6,852,757	02/2005	Jerome et al			
		6,858,416	02/2005	Murkerji et al			

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. 604-756	SERIAL NO. 10/555,757
APPLICANT HARBIGE et al		
(Use several sheets if necessary)	FILING DATE November 7, 2005	TC/A.U. Unassigned

		2001/0047036	11/2001	Vanderhoof et al			
		2002/0022658	02/2002	Das			
		2002/0051964	05/2002	Surai et al			
		2002/0065319	05/2002	Horrobin			
		2002/0072539	06/2002	Mechoulam et al			
		2002/0081366	06/2002	Cain et al			
		2002/0082436	06/2002	Jerome et al			
		2002/0198177	12/2002	Horrobin			
		2003/0013759	01/2003	Das			
		2003/0031753	02/2003	Watkins et al			
		2003/0032674	02/2003	Hwang			
		2003/0045578	03/2003	Horrobin			
		2003/0166723	09/2003	Nakajima et al			
		2004/0014810	01/2004	Horrobin et al			
		2004/0019109	01/2004	Owman et al			
		2004/0039058	02/2004	Ursin et al			
		2004/0043963	03/2004	Wadstein			
		2004/0048926	03/2004	Hoffman et al			
		2004/0048927	03/2004	Horrobin			
		2004/0096468	05/2004	Changaris			
		2004/0102519	05/2004	Llewellyn			
		2004/0162348	08/2004	Peet et al			
		2004/0171688	09/2004	Bar-Tana			
		2004/0208939	10/2004	Sears et al			
		2004/0220081	11/2004	Kreitz et al			
		2004/0229950	11/2004	Vanderhoek			
		2004/0248763	12/2004	Freeman et al			
		2004/0266874	12/2004	Akimoto et al			
		2005/0009779	01/2005	Killiaan et al			
		2005/0027004	02/2005	Kyle et al			
		2005/0042256	02/2005	Decombaz et al			
		2005/0123479	06/2005	Ferrante			
		4,701,469 A	10/1987	Mendy et al			
		2003/045460 A	03/2003	Fogelman et al			
		3,993,775	11/1976	Williams			
		2004/0209953 A1	10/2004	Wai Lee			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
EP 0490 561	03/1996	EP				
EP 0 568 608	09/2000	EP				

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	604-756	10/555,757
(Use several sheets if necessary)	APPLICANT	
	HARBIGE et al	
	FILING DATE	TC/A.U.
	November 7, 2005	Unassigned

		EP 0 679 057	08/1999	EP				
		EP 0 707 850	04/1996	EP				
		EP 0 711 503	05/1996	EP				
		EP 0 766 961	04/1997	EP				
		EP 0 796 238	05/2000	EP				X
		EP 0 790 056	08/1997	EP				
		EP 0 800 584	05/2003	EP				
		WO 96/40106	12/1996	WO (Equivalent to EP 0831805)				
		EP 0 891 773	01/1999	EP				X
		EP 0 920 300	04/2003	EP				
		EP 0 956 011	06/2002	EP				
		EP 0 956 013	04/2003	EP				
		WO 98/46763	10/1998	WO (Equivalent to EP 0975766)				
		EP 0 994 705	03/2004	EP				
		WO 98/46764	10/1998	WO (Equivalent to EP 0996732)				
		WO 98/46765	10/1998	WO (Equivalent to EP 1007691)				
		EP 1 035 846	07/2002	EP				X
		EP 1 077 061	02/2001	EP				X
		EP 1 091 659	05/2002	EP				X
		EP 1 129 711	01/2004	EP				
		WO 00/34791	06/2000	WO (Equivalent to EP 1137949)				
		WO 00/40705	07/2000	WO (Equivalent to EP 114252)				X
		WO 01/17524	03/2001	WO (Equivalent to EP 1214067)				
		WO 01/13733	03/2001	WO (Equivalent to EP 1221861)				
		EP 1 221 867	11/2004	EP				
		EP 1 292 288	09/2004	EP				
		EP 1 325 747 A2	07/2003	EP				
		EP 1 325 747 A3	07/2003	EP				
		EP 1 342 787	09/2003	EP				
		WO 02/092073	11/2002	WO (Equivalent to EP 1392278)				
		WO 02/05849	01/2002	WO (Equivalent to EP 1476171)				
		WO 03/075670	09/2003	WO (Equivalent to EP 1489915)				
		EP 1506778	02/2005	EP				
		WO 03/092628	11/2003	WO (Equivalent to EP 1503715)				
		GB 1 490 603	11/1977	GB				
		GB 2 409 644	07/2005	GB				
		DE 100 29 562	03/2001	DE				X
		DE 19503993	08/1996	DE				X
		WO 98/16215	04/1998	WO				
		WO 00/12720	03/2000	WO				
		WO 00/09476	02/2000	WO				

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

604-756**10/555,757**

APPLICANT

HARBIGE et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

November 7, 2005**Unassigned**

	WO 00/21524	04/2000	WO				
	WO 00/44360	08/2000	WO				
	WO 00/53637	09/2000	WO				
	WO 00/74669	12/2000	WO				
	WO 01/10989	02/2001	WO				
	WO 01/17366	03/2001	WO				
	WO 02/047493	06/2002	WO				
	WO 03/013276	02/2003	WO				
	WO 02/096408	12/2002	WO				
	WO 02/102757	12/2002	WO				
	WO 2003/043972	05/2003	WO				
	WO 03/075003	09/2003	WO				
	WO 2004/012753	02/2004	WO				
	WO 2004/024136	03/2004	WO				
	WO 2004/028529	04/2004	WO				
	WO 2004/084882	10/2004	WO				
	WO 2004/105517	12/2004	WO				
	WO 2005/037848	04/2005	WO				
	WO 2005/063231	07/2005	WO				
	WO 90/12080	10/1990	WO				
	WO 96/05164	02/1996	WO				
	WO 97/04127	02/1997	WO				
	WO 98/16215	04/1998	WO				
	WO 98/44917	10/1998	WO				
	WO 03/013497 A	02/2003	WO				
	WO 01/97793 A	12/2001	WO				
	EP 0 609 078 A	08/1994	EP				
	EP 0 505 817 A	09/1992	EP				
	WO 2005/018632 A1	03/2005	WO				
	WO 01/97793 A2	12/2001	WO				
	WO 99/51560 A1	10/1999	WO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Co-pending Application Serial No. 10/567,778, filed February 9, 2006 (Attorney Docket No. 604-770).
	Co-pending Application Serial No. 11/791,606, filed May 25, 2007 (Attorney Docket No. 604-807).
	Co-pending Application Serial No. 11/885,255, filed August 29, 2007 (Attorney Docket No. 504-812).
	Akoh, C.C.; "Structured lipids - enzymatic approach"; <i>Inform</i> ; Vol. 6:9, pp. 1055-1061 (1995).
	Bradley, D.G., "Designer fats; turning scientific advance into consumer benefit"; <i>Lipid Technology</i> ; pp. 89-91, July 1997.
	Christensen, M.S., et al; "Intestinal absorption and lymphatic transport of eicosapentaenoic 9EPA), docosahexaenoic 9DHA), and decanoic acids: dependence on intramolecular triacylglycerol structure"; <i>Am. J. Clin. Nutr.</i> Vol. 61, pp. 56-61 (1995).
	Christensen, M.S., et al; "Absorption of triglycerides with defined or random structure by rats with biliary and pancreatic diversion"; <i>Lipids</i> ; Vol. 30, No. 6, pp. 521-526 (1995).

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

604-756**10/555,757**

APPLICANT

HARBIGE et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

November 7, 2005**Unassigned**

	Decker, E.A.; "The role of stereospecific saturated fatty acid positions on lipid nutrition"; <i>Nutr. Rev.</i> ; Vol. 54, No. 4, pp 108-110 (1996).
	Dehesh, K., "Production of high levels of 8:0 and 10:0 fatty acids in transgenic canola by overexpression of Ch FatB2, a thioesterase cDNA from <i>Cuphea Hookeriana</i> "; <i>The Plant Journal</i> ; Vol. 9, No. 2; pp. 167-172 (1996).
	Gurr, M.; "Fat digestion and assimilation"; <i>Lipid Technology</i> ; pp. 94-97, July 1997.
	Hauumann, B.F.; "Structured lipids allow fat"; <i>Inform</i> Vol. 8, No. 10, pp. 1004-1011 (1997).
	Ikeda I., et al; "Lymphatic absorption of structured glycerolipds containing medium-chain fatty acids and linoleic acid, and their effect on cholesterol absorption in rats"; <i>Lipids</i> , Vol. 26, No. 5, pp. 369-373 (1991).
	Jandacek, R.J., et al; "The rapid hydrolysis and efficient absorption of triglycerides with octanoic acid in the 1 and 3 positions and long-chain fatty acid in the 2 position"; <i>Am J. Clin. Nutr.</i> ; Vol. 45, pp. 940-945 (1987).
	Jensen, M.M., et al; "Intestinal absorption of octanoic, decanoic, and linoleic acids: Effect of triglyceride structure"; <i>Ann. Nutr. Metab</i> , Vol. 38, pp. 104-116 (1994).
	Kenler A.S., et al; "Early enteral feeding in postsurgical cancer patients"; <i>Annals of Surgery</i> ; Vol. 223, No. 3, pp. 316-333 (1996).
	Kennedy, J.P.; "Structured Lipids: Fats of the Future"; <i>Food Technology</i> ; pp. 76-83 (1991).
	Kritchevsky, D. ; "Fatty acids, triglyceride structure, and lipid metabolism"; <i>Nutr. Biochem</i> , Vol. 6, pp. 172-178 (1995).
	Kritchevsky, D., et al; "Cholesterol vehicle in experimental atherosclerosis Part 10. Influence of specific saturated fatty acids"; <i>Exp. Molec. Pathol</i> ; Vol. 6, pp. 394-401 (1967).
	Kritchevsky, D., et al; "Cholesterol vehicle in experimental atherosclerosis VII. Influence of naturally occurring saturated fats"; <i>Med. Pharmacol. Exp.</i> ; Vol. 12, pp. 315-320 (1965).
	Kritchevsky, D. et al; "Cholesterol vehicle in experimental atherosclerosis Part 15. Randomized butter and randomized lard"; <i>Atherosclerosis</i> ; Vol. 27, pp. 339-345 (1977).
	Kritchevsky D., et al; "Experimental atherosclerosis in rabbits fed cholesterol free diets. Part 10. Cocoa butter and palm oil"; <i>Atherosclerosis</i> ; Vol. 41, pp. 279-284 (1982).
	Kritchevsky, D. et al; "Influence of triglyceride structure on experimental atherosclerosis in rabbits"; <i>FASEB J</i> 10, A187 (1996).
	Kritchevsky D, Tepper SA, Kim HK, Story JA, Vesselinovitch D, and Wissler RW. 1976. Experimental atherosclerosis in rabbits fed cholesterol free diets 5. Comparison of peanut, corn, butter and cocon ut oils. <i>Exp. Molec. Pathol.</i> 24: 375-391.
	Kritchevsky, D., et al; "Influence of triglyceride structure on experimental atherosclerosis in rabbits"; <i>FASEB J</i> 9, A320 (1995).
	Kritchevsky,k D., et al; "Thyroid hormone and experimental atherosclerosis in rabbits"; <i>Atherosclerosis</i> ; Vol. 23, pp. 249-252 (1976).
	Kubow, S., et al; "The influence of positional distribution of fatty acids in native, interesterified and structure-specific lipds on lipoprotein metabolism and atherogenesis"; <i>Nutr. Biochem</i> ; Vol. 7, pp. 530-541 (1996).
	Mattson, F.H., et al; "The digestion and absorption of triglycerides"; <i>J. Biol. Chem.</i> ; Vol. 239, pp. 2772-2777 (1964).
	Metolli, A.M., et al; "Medium-chain lipds: new sources, uses"; <i>Inform</i> ; Vol. 8, No. 6, pp. 597-603 (1997).
	Myher, J.J., et al; "Acylglycerol Structure of peanut oils of different atherogenic potential"; <i>Lipids</i> ; Vol. 12; pp. 765-878 (1977).
	Sadou, H. et al; "Differential incorporation of fish-oil eicosapentaenoate and docosahexaenoate into lipds of lipoprotein fractions as related to their glycerol esterification: a short-term (postprandial) and long-term study in healthy humans"; <i>Am J. Clin Nutr.</i> ; Vol. 62, pp. 1193-1200 (1995).
	Small, D.M.; "The effects of glyceride structure on absorption and metabolism"; <i>Annu. Rev. Nutr.</i> ; Vol. 11, pp. 413-434 (1991).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

604-756

SERIAL NO.

10/555,757

APPLICANT

HARBIGE et al

(Use several sheets if necessary)

FILING DATE

November 7, 2005

TC/A.U.

Unassigned

	Voelker, T.A., et al; "Fatty acid biosynthesis redirected to medium chains in transgenic oilseed plants"; <i>Science</i> ; Vol. 257, pp. 72-74 (1992).
	Zock, P.L., et al; "Positional distribution of fatty acids in dietary triglycerides: effects on fasting blood lipoprotein concentrations in humans"; <i>Am. J. Clin. Nutr.</i> ; Vol. 61, pp. 48-55 (1995).
	Kritchevsky, D.; "Fatty acids, triglyceride structure, and lipid metabolism"; <i>Nutr. Biochem</i> ; Vol. 6, pp. 172-178 (1995).
	Miles, E.A., et al; "The influence of different combinations of γ -linolenic acid, stearidonic acid and EPA on immune function in healthy young male subjects"; <i>British Journal of Nutrition</i> ; Vol. 91, pp 893-903 (2004).
	McCormick, J.N., et al; "Immunosuppressive effect of linolenic acid"; <i>The Lancet</i> ; p 508 (1977).
	Demmelmair, H., et al; "Influence of formulas with borage oil or borage oil plus fish oil on the arachidonic acid status in premature infants"; <i>Lipids</i> , Vol. 36, No. 6; pp 555-566 (2001).
	Thijs, C., et al; "Essential fatty acids in breast milk of atopic mothers: comparison with non-atopic mothers, and effect of borage oil supplementation"; <i>European Journal of Clinical Nutrition</i> ; Vol. 54, pp. 234-238 (2000).
	Leventhal, L.J., et al; "Treatment of Rheumatoid Arthritis with Blackcurrant Seed Oil"; <i>British Journal of Rheumatology</i> ; Vol. 33, pp. 847-852 (1994).
	Zurier, R.B., et al; "Gamma-Linolenic Acid Treatment of Rheumatoid Arthritis"; <i>Arthritis & Rheumatism</i> ; Vol. 39, No. 11, pp. 1808-1817 (1996).
	Patent Abstracts of Japan, Vol. 1995, No. 01, 28 February 1995 & JP 06 279311 A (Sagami Chem Res Center; others: 01), 04 October 4, 1994 (Abstract).
	Patent Abstracts of Japan, Vol. 1996, No. 03, 29 March 1996 & JP 07 309773 A (Sagami Chem Res Center; others: 01), 28 November 1995 (Abstract).
	Mechoulam, R., et al; "Cannabinoids and brain injury: therapeutic implications"; <i>Trends in Molecular Medicine</i> ; Vol. 8, No. 2; pp. 58-61 (2002) XP-002381881.
	Database Biosis (Online), Biosciences Information Service, Philadelphia, PA, USA; March 2003; Rockwell C.E., et al; "Inhibition of interleukin-2 (IL-2) by the endogenous cannabinoid, 2-arachidonyl glycerol, is partly mediated through peroxisome proliferators-activated receptor-gamma (PPAR-gamma)"; Database accession no. PREV200300230725 abstract & <i>Toxicological Sciences</i> , Vol. 72, No. s-1, March 2003, p. 328, 42 nd Annual Meeting of the Society of Toxicology; Salt Lake City, UT, USA; March 9-13, 2003, ISSN: 1096-6080.
	Database Embase (Online) Elsevier Science Publishers, Amsterdam, N1; 2005, Kaplan, B. L.F., et al; "2-Arachidonoyl-glycerol suppresses interferon- γ production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2", XP-002381886 (abstract); <i>Journal of Leukocyte Biology</i> ; Vol. 77 pp. 966-974 (2005).
	Ouyang, Y., et al; "Suppression of Interleukin-2 by the Putative Endogenous Cannabinoid 2-Arachidonyl-Glycerol is Mediated through Down-regulation of the Nuclear Factor of Activated T Cells"; <i>Molecular Pharmacology</i> ; Vol. 53, pp. 676-683 (1998) XP-002381882.
	Venderova, K., et al; "Differential effects of endocannabinoids on [³ H]-GABA uptake in the rat globus pallidus"; <i>Experimental Neurology</i> ; Vol. 194, pp. 294-287 (2005).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.